CompletedNot Applicable

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD

United States11 participantsStarted 2013-02-25

Plain-language summary

The purpose of his study is to evaluate the long term safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry Age-Related Macular Degeneration (AMD) from one to five years following the surgical procedure to implant the MA09-hRPE cells.

Who can participate

Age range55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must have been treated with hESC-RPE cell transplant in the core protocol. * Able to understand and willing to sign the informed consent to participate in the follow up study. Exclusion Criteria: \- There are no exclusion criteria.

What they're measuring

Safety assessed by Adverse Events (AEs) of special interest in regards to the investigational product

Timeframe: 4 years

Trial details

NCT IDNCT02463344

SponsorAstellas Institute for Regenerative Medicine

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-08-19

View on ClinicalTrials.gov More Age-Related Macular Degeneration trials